XL mutagenesis kit (Stratagene, Santa Clara, CA) and the mutagenic primers shown in supplementary Table I . The recombinant adenoviruses were packaged in 911 cells, amplifi ed in human embryonic kidney 293 (HEK293) cells, purifi ed, and titrated as described ( 12 ) .
The human LCAT cDNA in the pENTR221 vector was a gift of Dr. J. A. Kuivenhoven (University of Amsterdam). The LCAT cDNA was amplifi ed using primers that contained restriction sites for BglII and EcoRV, respectively, at the 5 ′ and 3 ′ ends, as shown in supplementary Table I . The LCAT cDNA was digested with BglII and EcoRV and cloned into the corresponding sites of the pAdTrack-CMV vector. The recombinant adenovirus was constructed, purifi ed, and titrated as described ( 12 ) .
ApoA-I production, purifi cation, and use for functional and physicochemical studies. Wild-type (WT) apoA-I, apoA-I [218] [219] [220] [221] [222] mutant, and apoA-I[E223A/K226A] mutant protein were obtained from the culture media of HTB-13 cells grown in roller bottles following infection with adenoviruses expressing the corresponding proteins. For protein production, the culture medium was collected every 24 h, dialyzed against 25 mM ammonium bicarbonate, and lyophilized. For the purifi cation of WT apoA-I and apoA-I[E223A/K226A] mutant, the lyophilized medium was resuspended in 0.01M Tris (pH 8), fi ltered, and passed through a 5 ml HiTrap Q HP column (GE Healthcare). The proteins were eluted with linear gradient of 1M NH 4 CO 3 in the Tris buffer, as described previously ( 1 ) . The apoA-I[218-222] mutant was purifi ed with the same procedure under denaturing conditions (8M urea) to facilitate the dissociation of apoA-I from other proteins that coelute with mutant apoA-I under native conditions. The purity of the apoA-I preparation was assessed by SDS-PAGE, and fractions greater than 95% pure were pooled.
ABCA1-dependent cholesterol effl ux and LCAT assays. ABCA1-
dependent effl ux of cholesterol was measured in cultures of J774 macrophages in which expression of ABCA1 was induced by a cAMP analog using WT and mutant apoA-I forms as cholesterol acceptors. The J774 mouse macrophages were labeled with 0.3 Ci/ml [ 14 C]cholesterol ([4-14 C]cholesterol, 0.04 mCi/ml of specifi c activity 50 mCi/mmol; Perkin-Elmer Life Sciences) for 24 h and then treated with 0.3 mM cpt-cAMP [8-(4-chloro phenylthio)-cAMP] for 24 h. Cholesterol effl ux was determined as described previously ( 1 ) .
LCAT was purifi ed as described ( 14 ) from the culture medium of human HTB13 cells infected with an adenovirus expressing the human LCAT cDNA ( 22 ) . The reconstituted HDL (rHDL) particles used as the substrate contained cholesterol, and [ 14 C] cholesterol, ␤ -oleoyl-␥ -palmitoyl-L-␣ -phosphatidylcholine (POPC), and apoA-I. rHDL was prepared by the sodium cholate dialysis method as described previously ( 23 ) . rHDL particles without 14 Ccholesterol containing mutant forms of apoA-I were prepared with the same procedure to measure their size by electron microscopy (EM). The size of these particles was determined from the negatives of the EM images. The enzymatic reactions and the derivation of the apparent V max and K m were carried out as described previously ( 13 ) .
Physicochemical measurements. Derivation of far-UV spectra, thermal and chemical denaturation profi les, and 8-anilino-1-naphthalene-sulfonate (ANS) fl uorescence spectra of the WT apoA-I, apoA-I[218-222] mutant, and apoA-I[E223A/K226A] mutant are described in the supplementary methods.
Animal studies. ApoA 
) C57BL/6J mice ( 24 ) were purchased from Jackson Laboratories (Bar Harbor, (E223, K226) residues, located within or in the vicinity of the 220-231 region, on the biogenesis of HDL and the properties of apoA-I. The rationale for the alteration of these residues that reside within the 222-226 domain was based on the signifi cance of this region for the structure of apoA-I. The crystal structure at 3.2 Å resolution of a truncated, lipid-free form of apoA-I [ ⌬ (1-43)] that lacks the amino terminal domain indicated that, with the exception of the 220-227 region, apoA-I consists of a nearly continuous amphipathic ␣ -helical sequence that is punctuated by small or pronounced kinks ( 16, 17 ) . Most recently the three-dimensional structure of a dimeric truncated form of lipid-free apoA-I[ ⌬ (185-243)] was determined at 2.2 A o resolution ( 18 ) . The structure showed that the N-terminal domain stabilizes the apoA-I dimer in solution and forces it to an antiparallel confi guration that is similar to the confi guration that the two apoA-I monomers assume when bound to discoidal HDL particles (16) (17) (18) (19) . In this confi guration, it was proposed that the unstructured loop consisting of residues 220-227 allows helices 10 of each monomer to register in antiparallel orientation relative to the other.
In the present study, physicochemical studies and in vitro experiments determined how the mutations affected the structure of apoA-I and the ability of the mutant proteins to promote ABCA1-mediated cholesterol effl ux and to activate LCAT. Adenovirus-mediated gene transfer of the apoA-I[218-222] mutant in apoA-I Ϫ / Ϫ × apoE Ϫ / Ϫ mice led to the formation of only pre-␤ -HDL particles and a small number of discoidal HDL particles. In contrast to previous studies (11) (12) (13) , this defect, observed for the fi rst time, could not be corrected by coexpression of the apoA-I[218-222] mutant and LCAT. Expression of the apoA-I[E223A/K226A] mutant in apoA-I Ϫ / Ϫ mice caused small alterations in the apoA-I structure and the HDL phenotype, suggesting that these residues also contribute to the effi cient formation of HDL. In addition to the drastic effect of the L218A/L219A/ V221A/L222A mutations on the biogenesis of HDL, the mutants also inhibited the ability of lipid-free apoA-I to promote transendothelial transport ( 20 ) , as well as its bactericidal activity against Gram-negative bacteria ( 21 ) , indicating the importance of the 218-222 residues for the functions of apoA-I.
EXPERIMENTAL PROCEDURES

Materials
Materials not mentioned in this section have been obtained from sources described previously ( 2, 14 ) .
Methods
Generation of adenoviruses expressing the wild-type and the mutant apoA-I forms and human LCAT. The apoA-I gene lacking the BglII restriction site that is present at nucleotide position 181 of the genomic sequence relative to the ATG codon of the gene was cloned into the pCDNA3.1 vector to generate the pCDNA3.1-apoA-I( ⌬ BglII) plasmid as described ( 12 distributed in the HDL2 and HDL3 region and that the apoA-I[E223A/K226A] and apoA-I[218-222] mutants were predominantly distributed in the HDL3 and, to a lesser extent, the HDL2 region ( Fig. 2A , B ) . The apoA-I[218-222] mutant was characterized by low levels of apoA-I and increased levels of mouse apoE that fl oated in the HDL2/ HDL3 ( Fig. 2C and supplementary Fig. I-A, B ) and in the VLDL/IDL/LDL region.
Analysis of the HDL fractions 6 and 7 obtained following density gradient ultracentrifugation by EM showed that the WT apoA-I as well as the two apoA-I mutants (apoA-I[E223A/K222A] and apoA-I[218-222]) generated spherical particles ( Fig. 2D-F ) . Two-dimensional gel electrophoresis of plasma showed that WT apoA-I formed normal pre-␤ -and ␣ -HDL subpopulations ( Fig. 2G ) ; the apoA-I[E223A/K226A] mutant formed predominantly ␣ 2, ␣ 3, and ␣ 4 and had increased amount of pre-␤ subpopulations ( Fig. 2H ) ; and the apoA-I[218-222] mutant formed only pre-␤ , ␣ 4, and ␣ 3 subpopulations ( Fig. 2I ) .
To clarify whether the HDL particles observed in Table II ). Separation of the plasma by density gradient ultracentrifugation and SDS-PAGE analysis of the fractions showed that WT apoA-I was distributed predominantly in the HDL2/ HDL3 region ( Fig. 3A ) . EM analysis of the fractions 6 and 7 obtained by density gradient ultracentrifugation of the plasma showed that WT apoA-I generated spherical particles ( Fig. 3B ) . Two-dimensional gel electrophoresis showed that the plasma of mice expressing WT apoA-I contained the normal pre-␤ -and ␣ -HDL subpopulations ( Fig. 3C ) . SDS-PAGE analysis of plasma fractions obtained from mice expressing the apoA-I[218-222] mutant showed the presence of small amounts of the mutant protein in the HDL3 region ( Fig. 3D ) . The L218A/L219A/V221A/L222A mutations in apoA-I resulted in a great increase in plasma apoA-IV that fl oated in the IDL/LDL/HDL2/HDL3 region ( Fig. 3D and supplementary Fig. II ) and the presence of apoB-48 in the HDL region ( Fig. 3E ) . The apoA-I[218-222] mutant generated few discoidal particles as well as particles corresponding in size to VLDL (48.5 ± 15 nm), IDL (28.8 ± 3 nm), and LDL (20.2 ± 2.5 nm) ( Fig. 3F ) . The appearance of the LDL-and IDL-sized particles is also supported by the presence of apoB-48 in fractions 6 and 7 used for the EM analysis ( Fig. 3E ). The plasma of mice expressing the apoA-I[218-222] mutant contained only pre-␤ -HDL particles ( Fig. 3G ) . The relative migration of the particles generated by WT apoA-I and the apoA-I[218-222] mutant was established by two-dimensional gel electrophoresis of mixtures of the plasmas containing these two apoA-I forms ( Fig. 3H ) . Previous studies have shown that the low HDL levels and the abnormal HDL phenotypes of some natural apoA-I ME). Mice defi cient for apoA-I Ϫ / Ϫ and apoE Ϫ / Ϫ were a gift of Dr.
Fayanne Thorngate and Dr. David Williams ( 25 ) or were obtained by crossing apoA-I Ϫ / Ϫ with apoE Ϫ / Ϫ ( 26 ). The mice were maintained on a 12 h light/dark cycle and standard rodent chow. All procedures performed on the mice were in accordance with National Institutes of Health guidelines and followed a protocol (AN-14219.2012.10) approved by the Institutional Animal Care and Use Committee (IACUC) . ApoA-I Ϫ / Ϫ or apoA-I Ϫ / Ϫ × apoE Ϫ / Ϫ mice, 6-8 weeks of age, were injected via the tail vein with 1-2 × 10 9 pfu of recombinant adenovirus per animal. The animals were euthanized four days after injection following a four-hour fast. Five to six mice were used for each set of experiments. Determination of plasma lipids and apoA-I levels, fractionation of plasma by fast-protein liquid chromatography (FPLC), and density gradient ultracentrifugation EM of HDL and two-dimensional gel electrophoresis of plasma are as described ( 1, 2, 27 and supplementary methods).
Statistics. Statistical analyses were performed by two-tailed
Student t -test with equal variance.
RESULTS
Expression of the apoA-I transgene following adenovirus infection
Total hepatic RNA was isolated from the livers of apoA-I Ϫ / Ϫ four days after infection with adenoviruses expressing the WT apoA-I, apoA-I[218-222] mutant, and apoA-I [E223A/K226A] mutant. The relative expression of the WT and the mutant apoA-I transgenes was determined by qPCR as described in the Experimental Procedures. This analysis showed that the expression of WT and the apoA-I [218-222] mutant were comparable, whereas the expression of apoA-I[E223A/K226A] was approximately 165% of that of WT apoA-I (supplementary Table II) .
Plasma lipid and apoA-I levels and FPLC profi les
Plasma lipids and apoA-I were determined four days after infection of apoA-I Ϫ / Ϫ mice with adenoviruses expressing the WT and the two apoA-I mutants. It was found that the apoA-I[218-222] mutant decreased plasma cholesterol and apoA-I levels to approximately 15% as compared with WT apoA-I. The plasma apoA-I levels of the apoA-I[E223A/K226A] mutant were not statistically different from those of WT apoA-I, whereas the plasma cholesterol levels were signifi cantly lower (62% as compared with WT apoA-I) ( Fig. 1A , B ) . The plasma triglycerides of the apoA-I[E223A/K226A] mutant were slightly increased as compared with wild-type apoA-I ( P < 0.05) (supplementary Table II ). FPLC analysis of plasma from apoA-I Ϫ / Ϫ mice infected with the recombinant adenovirus expressing either WT apoA-I or the two apoA-I mutants showed that in all cases cholesterol was distributed in the HDL region and that the HDL cholesterol peak of the apoA-I[218-222] mutant was greatly diminished ( Fig. 1C ) .
Fractionation of plasma, EM analysis, and twodimensional electrophoresis of plasma of apoA-I ؊ / ؊ mice expressing the WT and the mutant forms of apoA-I Fractionation of plasma by density gradient ultracentrifugation and subsequent analysis of the resulting fractions by SDS-PAGE showed that the WT apoA-I was equally mutant did not have an HDL cholesterol peak ( Fig. 4A ) . Coexpression of the apoA-I[218-222] mutant and LCAT had a small effect on the HDL cholesterol peak, but it generated a pronounced cholesterol shoulder in the VLDL/ IDL/LDL region ( Fig. 4A ) . Density gradient ultracentrifugation of plasma followed by SDS-PAGE analysis of the fractions showed that a small amount of the mutant apoA-I was found in the HDL3. In addition, the plasma concentration of mouse apoA-IV increased, and the protein shifted toward the VLDL/IDL/LDL region ( Fig. 4B ) . EM analysis of the HDL fraction obtained by density gradient ultracentrifugation showed the presence of small number of spherical HDL particles, along with larger particles corresponding in size to LDL and IDL ( Fig. 4C ) . The appearance mutants could be corrected by excess LCAT (11) (12) (13) . To assess the potential insuffi ciency of LCAT that led to the generation of discoidal particles observed in and LCAT contained only small amount of pre-␤ -and ␣ 4-HDL particles ( Fig. 4E ).
Comparative analysis of the in vitro functions of WT apoA-I, apoA-I[218-222] mutant, and apoA-I[E223A/K226A] mutant
The secretion of WT and mutant forms of apoA-I in the culture medium of HTB-13 cells following infection of the of the LDL-and IDL-sized particles is also supported by the presence of apoB-48 in fractions 6 and 7 used for the EM analysis ( Fig. 4D ) . It is possible that the LDL-and IDLsized particles might arise by initial formation of apoA-IVcontaining HDL ( 28 ) and subsequent fusion of such HDL particles with apoB-containing lipoproteins ( Fig. 4C, D ) . Two-dimensional gel electrophoresis showed that the plasma of mice coexpressing the apoA-I[218-222] mutant Supplemental Material can be found at:
apoA-I followed by CD measurements showed that the apoA-I[218-222] mutant had a much more cooperative unfolding transition, indicating a more compact structure for this mutant protein, whereas the apoA-I[E223A/ K226A] mutant had a slightly less cooperative unfolding transition, indicating a slightly less compact structure for this mutant ( Fig. 6B and Table 1 ). The chemical unfolding profi le of the apoA-I[218-222] mutant, probed by intrinsic tryptophan fl uorescence, was identical to that of the WT protein, whereas the chemical unfolding of the apoA-I [E223A/K226A] mutant was less cooperative than the WT apoA-I ( Fig. 6C and Table 1 ). Overall, the apoA-I[E223A/ K226A] mutant appears to be thermodynamically destabilized and is quite distinct from the apoA-I[218-222] mutant. Finally, the ANS fl uorescence measurements indicated compared with that of WT apoA-I, and its ability to activate LCAT was 65% of the WT control ( Fig. 5A , B ) .
Effect of the L218A/L219A/V221A/L222A and E223A/ K226A mutations on the ␣ -helical content, thermal unfolding, chemical unfolding, and hydrophobic surface exposure of apoA-I To test whether the functional changes of the two apoA-I mutants are accompanied by changes in the structure and conformation of the protein, we used an array of biophysical assays to evaluate the effects of these mutations ( Fig. 6 ). Circular dichroism (CD) measurements indicated 7% and 4.2% loss of helical content for the apoA-I[218-222] mutant and the apoA-I[E223A/K226A] mutant, respectively ( Fig. 6A and Table 1 ). Thermal unfolding of L218A/L219A/V221A/L222A and E223A/K226A mutations alter the functional and physicochemical properties of apoA-I The in vitro experiments showed that, compared with WT apoA-I, the capacity of the apoA-I[218-222] mutant to promote ABCA1-mediated cholesterol effl ux and to activate LCAT was 20% and 66%, respectively. The capacity of the apoA-I[E223A/K226A] mutant to promote ABCA1-mediated cholesterol effl ux was slightly increased compared with that of the WT control, and the capacity to activate LCAT was 65% of the WT control. The changes in the physicochemical properties of the apoA-I[218-222] mutant included a 7% decrease in its ␣ -helical content, a more cooperative thermal unfolding transition (yet an identical chemical unfolding transition), and a 40% reduction of hydrophobic surfaces exposed to the solvent. The higher cooperativity observed during the thermal denaturation of this mutant suggests a more compact and stable structure, which may appear at odds with the lack of any observed stabilization during the chemical denaturation. The two methods, however, report on different aspects of the conformational change that follows protein denaturation (overall secondary structure versus that the apoA-I[218-222] mutant had a 40% reduction of hydrophobic surface exposure to the solvent, whereas the apoA-I[E223A/K226A] mutant had a 160% increase in the hydrophobic surface exposure to the solvent ( Fig. 6D and Table 1 ).
DISCUSSION
Rationale for selection of the mutations
Lipid-free or minimally lipidated apoA-I promotes ABCA1-mediated cholesterol effl ux and thus serves as an acceptor of cellular phospholipid and cholesterol ( 1, 30, 31 ) . Lipid-bound apoA-I is a physiological activator of LCAT ( 31 ) . The functional interactions between apoA-I and ABCA1 are important for cholesterol effl ux and the biogenesis of HDL ( 1, 32, 33 ) . To identify the specifi c Cterminal residues of apoA-I that are required for correct interactions with ABCA1 and/or LCAT that lead to the formation of mature ␣ -HDL particles, we introduced two sets of mutations that span the 218-226 region of apoA-I. The properties of the apoA-I[218-222] and apoA-I[E223A/ K226A] mutants thus generated were studied by in vitro experiments and adenovirus-mediated gene transfer. changes in the folding and stability of the C-terminal moiety of the protein where the mutated residues are or to changes in the interactions between the C-terminal and N-terminal domain that primarily affect the stability of the C-terminal domain. However, since the two methods of denaturation use different mechanisms to unfold the protein, the possibility that the stabilization seen during the immediate environment of the tryptophan residues). In apoA-I, all of the tryptophan residues are located in the N-terminal moiety of the molecule, and therefore, the lack of changes during chemical denaturation suggest that the thermodynamic stability of this domain is not affected by the mutation. Conversely, the altered thermal denaturation profi le can be explained by localized Values are means ± SD from three or four experiments. Parameters obtained from the indicated measurements are as follows: " ␣ -helix" is the percentage of ␣ -helical content of the protein as calculated from the molecular ellipticity of the protein sample at 222 nm; "T m " is middle point of the thermal denaturation transition (melting temperature); "slope" is the calculated slope of the linear component of the thermal denaturation transition, around the melting temperature; "n" is an indicator of the cooperativity of the thermal unfolding transition and is calculated using the Hill equation n = (log 81) / log (T 0.9 / T 0.1 ), where T 0.9 and T 0.1 are the temperatures where the unfolding transition reaches a fractional completion of 0.9 and 0.1; " ⌬ H" is the relative enthalpy change during the thermal denaturation; " ⌬ G D o " is the relative change in Gibbs free-energy during the chemical denaturation; "D 1/2 " is the guanidine HCl concentration at which the midpoint of chemical denaturation is achieved; "m" is the slope at the midtransition point of chemical denaturation; and "fold increase" is the increase in ANS fl uorescence in the presence of the protein relative to free ANS in the same buffer.
a Fold increase in signal compared with unbound ANS . apolipoproteins. Density gradient ultracentrifugation showed that the plasma of these mice contained only small amounts of apoA-I in the HDL3 and the lipoprotein-free ( d у 1.21 g/ml) fractions. EM analysis showed the presence of few discoidal HDL as well as spherical particles corresponding in size to LDL and IDL. This is compatible with the presence of apoB-48 and apoA-IV in the HDL density range. Two-dimensional gel electrophoresis of plasma showed that it contained only pre-␤ -HDL. These data indicated that in apoA-I Ϫ / Ϫ × apoE Ϫ / Ϫ mice, the apoA-I[218-222] mutant caused a defective lipidation of apoA-I, possibly due to defective apoA-I/ABCA1 interaction, which resulted in the generation of only pre-␤ -HDL particles that could not be converted to mature ␣ -HDL particles. Previous studies showed that C-terminal deletion mutants that remove the 220-231 region of apoA-I prevented the biogenesis of normal ␣ -HDL particles but allowed the formation of pre-␤ -HDL particles ( 1, 15 ) . Similar pre-␤ -HDL particles have been found in the plasma of ABCA1-defi cient mice and humans carrying ABCA1 mutations that are characterized by HDL defi ciency (36) (37) (38) . It appears that in apoA-I Ϫ / Ϫ mice, the diminished interactions between ABCA1 and the apoA-I[218-222] mutant observed in vitro give the opportunity to the mouse apoE to compete more effectively for the ABCA1 binding site ( 3 ) and thus to be lipidated. This will lead to the formation of spherical apoE-containing HDL particles that fl oat in the HDL2/HDL3 regions ( the thermal denaturation is dependent on the particular unfolding pathway utilized during heat denaturation should not be ruled out. Finally, although the four mutated amino acids in the apoA-I[218-222] mutants correspond to ‫ف‬ 5% of total hydrophobic amino acids of the protein, introduction of the mutations resulted in a 40% reduction of hydrophobic surface exposure, indicating that the residues L218/ L219/V221/L222 give rise to almost half of the exposed hydrophobic sites of apoA-I. Taken as a whole, these fi ndings suggest that the apoA-I[218-222] mutant greatly affects the structural integrity and conformational plasticity of apoA-I, effects that may at least partially underlie the observed changes in its in vitro and in vivo functions. The changes in the physicochemical properties of the apoA-I[E223A/K226A] mutant included a 4.2% decrease in its ␣ -helical content, a less cooperative thermal and chemical unfolding, and a 160% increase in the hydrophobic surface exposed to the solvent. These changes indicate that this mutant is thermodynamically destabilized and distinct from the apoA-I[218-222] mutant. that, at comparable levels of gene expression, the plasma cholesterol and apoA-I levels of mice expressing apoA-I[218-222] mutant were greatly reduced as compared with WT apoA-I. The plasma cholesterol reduction was due to the great decrease in the HDL cholesterol levels as determined by FPLC fractionation. Density gradient ultracentrifugation of plasma showed that, compared with WT apoA-I, the apoA-I[218-222] mutant was mainly distributed in the HDL3 fraction and its quantity was greatly reduced. The HDL fraction also contained substantial amount of mouse apoE and some apoA-IV. A sensitive analysis that can detect abnormalities in the pathway of HDL biogenesis is the two-dimensional gel electrophoresis of plasma. This analysis showed that the apoA-I[218-222] mutant when expressed in apoA-I Ϫ / Ϫ mice generated pre-␤ -and ␣ 4-HDL particles. Such particles were shown previously to undergo fast catabolism by the kidney ( 11, 34 ) . The ability of the apoA-I[218-222] mutant to form HDL particles was also assessed by EM analysis of the HDL fractions obtained by density gradient ultracentrifugation of plasma. This analysis showed the presence of spherical HDL particles.
We showed recently that apoE-or apoA-IV-containing HDL particles can be formed following a pathway similar to that used for the generation of apoA-I-containing HDL particles ( 28, 35 ) . Since the HDL fractions 6 and 7 analyzed by EM contained both apoA-I[218-222] mutant and mouse apoE, we considered the possibility that the observed spherical HDL particles in Fig. 2F might represent a mixture of apoA-I-and apoE-containing HDL.
To IDL-and LDL-sized particles in the HDL region that are enriched in apoA-IV and apoB-48. Phenotypes generated by mutagenesis of apoA-I can facilitate the identifi cation of similar phenotypes that may exist in the human population. Such phenotypes may serve in the diagnosis, prognosis, and potential treatment of specifi c dyslipidemias. The gene transfer studies with the apoA-I[E223A/K226A] mutant showed that, at similar level of gene expression, the plasma apoA-I levels and the EM profi le were comparable to those of WT apoA-I. The HDL was shifted toward the HDL3 region and the total HDL cholesterol levels for this mutant were two thirds of that obtained from apoA-I Ϫ / Ϫ mice expressing WT apoA-I. Slight differences were also observed in the two-dimensional pattern of this mutant, including increased ratio of pre-␤ -to ␣ -HDL particles and decreased ␣ 1-HDL particles. The in vitro experiments showed that the apoA-I[E223A/K226A] mutant is thermodynamically destabilized, has normal capacity to activate ABCA1, and has a modest reduction (65%) in its capacity to activate LCAT. Overall, the data suggest that the apoA-I[E223A/K226A] mutant had small but distinct effects on the properties of apoA-I and the biogenesis of HDL.
In previous studies, we showed that, when expressed in mouse models, naturally occurring point mutations in apoA-I insuffi ciently activate LCAT and lead to the accumulation of discoidal HDL particles in plasma. In this category belongs the apoA-I variants apoA-I ( 12 ) . A characteristic feature of these two categories of mutants, which are associated with low plasma HDL levels, is that the abnormal HDL phenotype could be corrected in vivo by gene transfer of human LCAT (11) (12) (13) . The phenotype produced by the apoA-I[218-222] mutant is distinct from all previously described phenotypes and cannot be corrected by overexpression of LCAT. In addition, the mutant protein had reduced capability to promote the ABCA1-mediated cholesterol effl ux. Although other interpretations are possible, the in vivo and in vitro data suggest that the interaction of the apoA-I[218-222] mutant with ABCA1 results in defective lipidation, which leads to the generation of pre-␤ -HDL particles that are not a good substrate for LCAT. If this interpretation is correct, one can envision a very precise initial orientation of the apoA-I ligand within the binding site of ABCA1 ( 3 ), similar to that described before for enzyme substrate interactions. A precise fi t of the apoA-I ligand into the ABCA1 binding site will allow its correct lipidation. The nascent particle thus formed can then undergo cholesterol esterifi cation by LCAT, which leads to the formation of mature ␣ -HDL particles. In contrast, incorrectly lipidated apoA-I becomes a poor substrate of LCAT.
Clinical implications
The apoA-I[218-222] mutant generated a unique aberrant HDL phenotype that has not been observed previously. The hallmark of this phenotype is low HDL levels, formation of pre-␤ -HDL and discoidal HDL that do not mature to spherical ␣ -HDL particles, and the presence of Supplemental Material can be found at:
